Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Primary central nervous system lymphoma (PCNSL) is a rare malignancy with limited understanding of its genetic underpinnings.
• Identifying genetic changes is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate copy number alterations and differentially expressed genes in PCNSL.
• To identify novel genes and pathways involved in PCNSL pathogenesis.
• To explore potential therapeutic targets for PCNSL.

Main Methods:

• High-resolution array-based comparative genomic hybridization (aCGH) was performed on 12 PCNSL samples.
• Expression profiling was conducted on 7 of the 12 PCNSL samples.
• Gene set enrichment analysis (GSEA) was used to identify involved pathways.

Main Results:

• The most frequent deletion occurred at 9p21.3, involving the CDKN2A gene in 66.7% of patients.
• Eight candidate genes (NPFFR2, C4orf7, OSMR, EMCN, TPO, FNDC1, COL12A1, and MSC) showed both copy number deletion and down-regulated expression.
• Low mRNA expression of C4orf7 was significantly associated with poor patient survival (P = .0425).
• Janus kinase-signal transducers and activators of transcription (JAK-STAT) and adhesion-related pathways were implicated in PCNSL pathogenesis.

Conclusions:

• This study identified novel tumor suppressor genes in PCNSL, including C4orf7, which may serve as therapeutic targets.
• The findings provide insights into the genetic landscape and pathogenesis of PCNSL.
• Further research into these identified genes and pathways could lead to improved treatment strategies for PCNSL.